Does Race Impact CF Diagnosis and Care?

Volume 10, Issue 1

Does Race Impact CF Diagnosis and Care?

In this issue:

BIPOC (Black, Indigenous, people of color): why is an accurate diagnosis of cystic fibrosis so often missed — or delayed, or misdiagnosed — in these groups? Why do people with CF from historically marginalized communities show an increased prevalence of Pseudomonas infection, more frequent pulmonary exacerbations, and higher mortality rates?

Those are some of the questions addressed by Dr. Jennifer Taylor-Cousar from National Jewish Health and Dr. Kamyron Jordan from Children’s Hospital Colorado — in this first issue of Volume 10 of eCysticFibrosis Review.

Learning objectives:

Describe variations in genetic ancestry that impact diagnosis and access to therapy for people with CF from historically marginalized communities, including Black, Indigenous, and people of color.
Describe the social determinants of health that affect outcomes in people with CF from historically marginalized communities, including Black, Indigenous, and people of color.

Authors:

Jennifer Taylor-Cousar, MD, MSCS

Medical Director, Clinical Research Services
Co-Director and CF TDC Director, Adult CF Program
Interim Associate Vice President of Diversity, Equity and Inclusion
Professor, Departments of Internal Medicine and Pediatrics
Divisions of Pulmonary, Critical Care and Sleep Medicine and Pediatric Pulmonary Medicine
National Jewish Health
Denver, CO

Kamyron Jordan, MD

Pediatric Pulmonary fellow Children’s Hospital Colorado

Aurora, CO

Guest Faculty Disclosures

Dr. Taylor-Cousar has indicated that she has served as an advisor for 4DMT; served on advisory committees or review panels for Vertex Pharmaceuticals Incorporated, AbbVie, Insmed, and Polarean; and received grant or research support from Vertex Pharmaceuticals Incorporated, Eloxx, and Proteostasis.

Dr. Jordan has indicated that he has no financial interests in or relationships with a commercial entity. 

Unlabeled/Unapproved Uses

Drs Taylor-Cousar and Jordan have indicated that there will be no references to the unlabeled or unapproved uses of any drugs or products. 

Program Directors:

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Peter J. Mogayzel, Jr., MD, PhD

Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD

Donna Peeler, RN

Clinical Nurse
Pediatric Clinic Coordinator
Johns Hopkins Cystic Fibrosis Center
Baltimore, MD

Guest Faculty Disclosures:

Dr. Jordan has indicated that he has no financial interests in or relationships with a commercial entity. 

Unlabeled/Unapproved Uses:

Drs Taylor-Cousar and Jordan have indicated that there will be no references to the unlabeled or unapproved uses of any drugs or products. 

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: May 12, 2022
Expiration date: May 11, 2024

Start Issue